Selective silencing of placental anti-angiogenic factors in invasive trophoblasts via membrane-fusion divalent siRNA delivery for preeclampsia therapy
Journal of Controlled Release · 2026
DOI: 10.1016/j.jconrel.2026.115152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2026. Verfasst von Wenqiang Qian und 9 weiteren Autor:innen. Beteiligte Einrichtung: Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China. Hauptthemen laut MEDLINE: Pre-Eclampsia, RNA, Small Interfering, Trophoblasts, Vascular Endothelial Growth Factor Receptor-1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Zhejiang Province Natural Science Foundation.
Abstract (Originalsprache)
Preeclampsia is a common and severe hypertensive disorder of pregnancy driven by placental dysfunction. In the absence of effective therapies, termination of pregnancy remains the only definitive treatment, resulting in significant maternal and fetal mortality. In this study, single-cell transcriptomic analysis of human placentae identified extravillous trophoblasts as a key pathogenic invasive cell subtype in preeclampsia, characterized by aberrant overexpression of fms-like tyrosine kinase-1 (Flt-1) and endoglin (Eng), the molecular sources of the soluble anti-angiogenic factors sFlt-1 and sEng. To coordinately modulate these pathogenic mediators, this study designed a novel dual-target divalent siRNA (dual-siRNA) to enhance molecular stability and enable simultaneous gene silencing, and further developed a ligand-functionalized membrane-fusogenic liposomal delivery system (iMFlip) targeting receptors highly expressed in invasive trophoblasts for selective dual-siRNA delivery. The optimized iMFlip@dual-siRNA exhibited favorable stability and low protein adsorption properties, and achieved efficient cytosolic siRNA delivery predominantly through membrane fusion, thereby substantially bypassing lysosomal degradation. In vitro, iMFlip@dual-siRNA markedly restored the invasion, migration and angiogenesis of hypoxia-injured HTR-8/SVneo cells. The subsequent pharmacodynamic studies showed that iMFlip@dual-siRNA simultaneously reduced circulating maternal sFlt-1 and sEng levels, alleviated placental vascular dysfunction and inflammatory microenvironment remodeling through reactivation of the PI3K/Akt/eNOS signaling pathway, and consequently improved maternal hypertension, proteinuria, and fetal growth restriction in a preeclamptic mouse model. Collectively, this study established a mechanism-driven therapeutic paradigm that integrated single-cell transcriptomic analysis-guided pathogenic target identification with advanced nucleic acid delivery strategies, offering a promising precision intervention approach for preeclampsia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
- Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China; Research Center for Clinical Pharmacy, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
- Research Center for Clinical Pharmacy, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
- Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China. Electronic address: sjx1996@zju.edu.cn.
- Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China. Electronic address: feiweidong@zju.edu.cn.
- Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China. Electronic address: chzheng@zju.edu.cn.
Förderung
- Zhejiang Province Natural Science Foundation
Zitieren
APA
Qian, W., Zhang, Y., Yao, Y., Zhu, X., Sun, D., Jiang, H., Jiang, P., Shang, J., Fei, W., & Zheng, C. (2026). Selective silencing of placental anti-angiogenic factors in invasive trophoblasts via membrane-fusion divalent siRNA delivery for preeclampsia therapy. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2026.115152
Vancouver
Qian W, Zhang Y, Yao Y, Zhu X, Sun D, Jiang H, et al. Selective silencing of placental anti-angiogenic factors in invasive trophoblasts via membrane-fusion divalent siRNA delivery for preeclampsia therapy. Journal of Controlled Release. 2026. doi:10.1016/j.jconrel.2026.115152
BibTeX
@article{Qian2026,
author = {Qian, Wenqiang and Zhang, Ying and Yao, Yao and Zhu, Xiaojun and Sun, Dongli and Jiang, Huidi and Jiang, Peiyue and Shang, Jiaxin and Fei, Weidong and Zheng, Caihong},
title = {Selective silencing of placental anti-angiogenic factors in invasive trophoblasts via membrane-fusion divalent siRNA delivery for preeclampsia therapy},
journal = {Journal of Controlled Release},
year = {2026},
doi = {10.1016/j.jconrel.2026.115152}
}
EUVIMED